4

12

1 Autism spectrum disorder trios from consanguineous populations are enriched

2 for rare biallelic variants, identifying 32 new candidate genes

3 Running title: Biallelic variants for autism and consanguinity

- 5 Ricardo Harripaul<sup>1,2</sup>§, Ansa Rabia<sup>1,3,4</sup>§, Nasim Vasli<sup>1</sup>, Anna Mikhailov<sup>1</sup>, Ashlyn Rodrigues<sup>1</sup>,
- 6 Stephen F. Pastore<sup>1</sup>, Tahir Muhammad<sup>1,2</sup>, Thulasi Thiruvallur Madanagopal<sup>1</sup>, Aisha Nasir
- 7 Hashmi<sup>1</sup>, Clinton Tran<sup>1</sup>, Cassandra Stan<sup>1</sup>, Katherine Aw<sup>1</sup>, Clement Zai<sup>1</sup>, Maleeha Azam<sup>5</sup>, Saqib
- 8 Mahmood<sup>3</sup>, Abolfazl Heidari<sup>6</sup>, Raheel Qamar<sup>5,7</sup>, Leon French<sup>2,8</sup>, Shreejoy Tripathy<sup>2,8</sup>, Zehra
- 9 Agha<sup>5,9</sup>, Muhammad Igbal<sup>10</sup>, Majid Ghadami<sup>11</sup>, Susan L. Santangelo<sup>12,13,14</sup>, Bita Bozorgmehr<sup>1</sup>,
- 10 Laila Al Ayadhi<sup>15</sup>, Roksana Sasanfar<sup>16</sup>, Shazia Maqbool<sup>17</sup>, James A. Knowles<sup>18</sup>, Muhammad
- 11 Ayub<sup>19,20\*</sup>, John B Vincent<sup>1,2,21\*</sup>
- 13 <sup>1</sup>Molecular Neuropsychiatry & Development (MiND) Lab, Campbell Family Mental Health
- 14 Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada;
- <sup>2</sup>Institute of Medical Science, University of Toronto, Toronto, ON, Canada;
- <sup>3</sup>University of Health Sciences, & NUR International University, Lahore, Pakistan;
- 17 4CMH Lahore Medical College & Institute of Dentistry, Lahore (affiliated with National
- 18 University of Medical Sciences, Rawalpindi), Pakistan;
- <sup>5</sup>Department of Biosciences, COMSATS University Islamabad, Islamabad, Pakistan;

20 <sup>6</sup>Sana Medical Genetics Laboratory, Qazvin, Iran; Reference Laboratory of Qazvin Medical 21 University, Qazvin, Iran; <sup>7</sup>Science and Environment Sector, ICESCO, Rabat, Kingdom of Morocco; 22 23 <sup>8</sup>Krembil Centre for Neuroinformatics, Centre for Addiction and Mental Health, Toronto, ON, 24 Canada; 25 <sup>9</sup>Department of Psychiatry, State University of New York at Buffalo; Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, USA; 26 27 <sup>10</sup>Department of Physiology, College of Medicine, King Saud University, Riyadh, Saudi Arabia; 28 <sup>11</sup>Department of Educational Sciences, Farhangian University, Tehran, Iran; <sup>12</sup>Center for Psychiatric Research, Maine Medical Center Research Institute, 509 Forest Avenue, 29 Portland, ME, 04101, USA; 30 <sup>13</sup>Tufts University School of Medicine, 136 Harrison Avenue, Boston, MA, 02110, USA; 31 32 <sup>14</sup>Department of Psychiatry, Maine Medical Center, 22 Bramhall Street, Portland, ME, 04102, 33 USA; 34 <sup>15</sup>Autism Research & Treatment Center, Department of Physiology, Faculty of Medicine, National Plan for Science and Technology (NPST), King Saud University, Riyadh, Saudi Arabia; 35 <sup>16</sup>Department of Psychiatry, Harvard Medical School, Boston, MA, USA; 36 37 <sup>17</sup>The University of Child Health Sciences, Children's Hospital, Lahore, Pakistan; <sup>18</sup>Human Genetics Institute of New Jersey and Department of Genetics, Rutgers University, 38 Piscataway, NJ, USA; 39 <sup>19</sup>Department of Psychiatry, Queens University Kingston, Kingston, ON, Canada;

- <sup>20</sup>Division of Psychiatry, University College London, London, UK;
- 40 <sup>21</sup>Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
- 41 §Equal contribution

48

- \*Correspondence should be addressed to:
- 43 Dr. John B. Vincent, Brain Molecular Science, Campbell Family Mental Health Research Institute,
- 44 Centre for Addiction and Mental Health (CAMH), 250 College Street, Toronto, ON, Canada, M5T
- 45 1R8; Email: john.vincent@camh.ca
- Dr. Muhammad Ayub, Division of Psychiatry, University College London, 149 Tottenham Ct Rd,
- 47 London W1T 7NF, United Kingdom. Email: m.ayub@ucl.ac.uk

Abstract

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

**Background:** Autism spectrum disorder (ASD) is a neurodevelopmental disorder that affects about 1 in 36 children in the united states, imposing enormous economic and socioemotional burden on families and communities. Genetic studies of ASD have identified de novo copy number variants (CNVs) and point mutations that contribute significantly to the genetic architecture, but the majority of these studies were conducted in populations unsuited for detecting autosomal recessive (AR) inheritance. However, several ASD studies in consanguineous populations point towards AR as an under-appreciated source of ASD variants. Methods: We used whole exome sequencing to look for rare variants for ASD in 115 probandmother-father trios from populations with high rates of consanguinity, namely Pakistan, Iran, and Saudi Arabia. Consanguinity was assessed through microarray genotyping. Results: We report 84 candidate disease-predisposing single nucleotide variants and indels, with 58% biallelic, 25% autosomal dominant/de novo, and the rest X-linked, in 39 trios. 52% of the variants were loss of function (LoF) or putative LoF (pLoF), and 47% nonsynonymous. We found an enrichment of biallelic variants, both in sixteen genes previously reported for AR ASD and/or intellectual disability (ID) and 32 previously unreported AR candidate genes (including DAGLA, ENPP6, FAXDC2, ILDR2, KSR2, PKD1L1, SCN10A, SHH, and SLC36A1). We also identified eight candidate biallelic exonic loss CNVs. Conclusions: The significant enrichment for biallelic variants among individuals with high Fron coefficients, compared with low F<sub>roh</sub>, either in known or candidate AR genes, confirms that

69	genetic architecture for ASD among consanguineous populations is different to non-
70	consanguineous populations. Assessment of consanguinity may assist in the genetic diagnostic
71	process for ASD.
72	<b>Keywords:</b> Autism spectrum disorder; Trio; Autosomal recessive; Consanguinity; Biallelic;
73	Candidate Genes
74	
75	

#### Introduction

Autism spectrum disorder (ASD) is characterized by deficits in social communication, repetitive/restricted behaviours and interests. Apart from a small percentage of individuals who recover (1), ASD is a life-long condition and only about 20% have good outcomes, as reported in a recent meta-analysis of longitudinal studies (2). Phenotypically, individuals with ASD are heterogeneous in their level of intellectual functioning, and co-morbid psychiatric and behavioural problems. These factors play an important role in the long term end points of the disease (3). In a systematic review the prevalence of ASD was estimated to be 0.76% internationally (4). In another systematic review of international data, the median estimate was 62/10,000 (5). In this review, the ASD prevalence showed little variation by geographic region, ethnic, cultural and socioeconomic factors (5).

The reported prevalence of ASD has increased with time. In the 1960s it was estimated to affect as few as 1 in 10,000 individuals (5), prevalence studies from the 1980s suggested that as many as 72 in 10,000 individuals had ASD, rising to 1% in the 2000s (5,6). More recent studies report prevalence rates of more than 2%. (7–9). In the United States the prevalence across eleven sites in 2016 was 18.5 per 1,000 (one in 54) children (10), and increasing to one in 36 in the most recent report (11). This increase is partly due to changes in diagnostic criteria, reporting practices, and increased awareness (12–15).

A systematic review of literature from South Asian countries reported a prevalence of ASD in the range of 0.09-1.07 % (16). To date, there has been no community study of ASD prevalence in Pakistan. Studies from child psychiatry clinics reported rates of 2.4% and 3.2%, 4.5%, 5% (17–

20). Clinical services and special schools for ASD are available in Pakistan, but are typically limited to major cities (21). The literature on clinical presentation is limited. One study with a small sample size shows symptoms consistent with studies elsewhere in the world (22).

Consanguineous marriages lead to a marked increase in the frequency of rare recessive disorders (23,24). Many genetic variants will only be pathogenic in recessive form; this includes variants for ID, and almost certainly for ASD too. Populations with a high proportion of consanguinity have been important for describing autosomal recessive genes in ID in Pakistan (25,26), Iran (27,28), Syria (29), and Saudi Arabia (30), yet, to date, relatively few reports of AR genes underlying ASD in consanguineous populations have been published (31–33). Previous work has highlighted recessive inheritance as an important component of the genetic architecture of ASD. For instance, a large study of consanguineous versus non-consanguineous families in India concluded that consanguinity increases the risk for ASD with an odds ratio of 3.22 (34). Morrow and colleagues used SNP microarrays to map homozygous loci in 104 small ASD families from the Middle East, Turkey and Pakistan, finding homozygous deletions implicating *SLC9A9*, *PCDH10*, *CNTN3* and others (31).

Research in outbred populations also supports AR inheritance as an important piece of the genetic puzzle for ASD. For example, it has been estimated that loss-of-function (LoF) recessive mutations contribute 3% of ASD genetics in two US-based case-control cohorts (35). These findings are not limited to population isolates or ethnic subgroups (36,37). Identification of recessive genes in outbred populations is problematic, as the analysis pipelines for WES/WGS data are non-optimal for discovering compound heterozygous mutations.

Despite the higher prevalence of recessive inheritance in consanguineous populations, data from studies of developmental disorder (DD) suggest that *de novo* variants are also prominent, albeit in a lower proportion e.g. in a UK study of 6040 families from the Deciphering Developmental Disorders (DDD) study, individuals of Pakistani ancestry had 29.8% *de novo* compared with 49.9% in the European ancestry UK population (38). In an Iranian ID study, the *de novo* rate was 27.86% (39).

Describing the genetic architecture of ASD is an important step towards understanding the pathogenesis of the disorder. There has been significant progress to date, and studies of ASD have shown that *de novo* copy number variants (CNVs) and point mutations play a prominent role, however, the majority of these studies have been conducted in outbred populations (40). Here, we report on a study of 84 genetic and 11 genomic variants (eight homozygous; 3 heterozygous) from a cohort of 115 ASD trios from three countries with a high frequency of consanguineous marriages (Pakistan, Iran, and Saudi Arabia).

#### **Materials and Methods**

## **Trio Family Ascertainment**

Institutional Research Ethics Board approval was received from the Centre for Addiction and Mental Health (CAMH) and the recruitment sites. A summary of the cohorts, collaborator contributions, ascertainment, and assessment tools, is in Table 1. Overall, we have collected DNA from 115 trios: 62 trios from Pakistan, 40 trios from Iran, and 13 trios from Saudi Arabia, comprised of 345 individuals.

#### Whole Exome Sequencing, Alignment and Variant Calling

Whole Exome Sequencing (WES) was performed on all samples using the Thruplex DNA-Seq (Rubicon Genomics) Library Preparation Kit with the Agilent SureSelect V5 Exome Capture kit.

DNA was sheared using a Covaris ME220 Focused-Sonicator 200 bp, which was verified using a Agilent 2100 Bioanalyzer System for fragment length distribution and quantification. All trios were sequenced on Illumina HiSeq 2500 or NovaSeq sequencing systems. Details of read QC, alignment, variant calling and prioritization are provided in Supplementary Materials, and summarized in Figure 1. Fifteen trios were previously run using the Ion Proton platform/Ion Ampliseq™ Exome kit (Life Technologies)- all were re-run using the Illumina platform except trio IABB3, for which a causative frameshifting deletion was detected in the VPS13B/Cohen syndrome gene.

#### Microarray genotyping and analysis.

Microarrays were run using DNA from 104 of the 115 ASD probands (where sufficient DNA was available), including 13 using Affymetrix CytoScanHD, 87 using Illumina CoreExome, and four with both arrays. CoreExome data in PLINK format was used for runs-of-homozygosity (RoH) analysis, using PLINK 1.9 (http://pngu.mgh.harvard.edu/purcell/plink). RoH data was used to generate an F-coefficient of consanguinity for the probands (and affected siblings),  $F_{RoH}$ , as described in McQuillan et al, 2008 (41), where  $F_{roh} = \sum L_{roh}/L_{auto}$ . Autosome size  $L_{auto}$  was estimated at 2,673,768 Kb. The CytoScanHD data was analysed using Chromosome Analysis Suite (ChAS), and a loss of heterozygosity (LoH) score was generated. For four samples that were run on both Illumina CoreExome and Affymetrix CytoScanHD arrays (probands from trios

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

IABB2, IABB3, IABB4, and IABB5), we were able to generate both Froh and LoH scores, which, as the relationship was almost linear (Pearson  $R^2 = 0.9971$ ) allowed us to convert LoH scores from CytoScanHD microarrays to Froh (Supplementary Materials). Comparison statistics were performed using GraphPad (https://www.graphpad.com/). **Copy Number Variant (CNV) analysis** CNV analysis of the CytoScanHD array data was performed using ChAS and PennCNV; for CoreExome data by the Illumina Genome Suite/CNVpartition and PennCNV. Evidence of homozygous loss CNVs was cross-references with WES data, using the Integrated Genome Viewer v2.3.5 (IGV: https://software.broadinstitute.org/software/igv/; (42), and CNVs corroborated in this manner were then checked by PCR. Further analysis/prioritization/validation of CNVs, including using WES data, is given in Supplementary Materials. **Cross-referencing with other datasets** In order to evaluate the strength of candidacy of the variants/genes identified here or to find supporting evidence, we cross-referenced our findings with other datasets listed below. We identified rare variants in the candidate genes we report here (Tables 2-4) that were either: 1. De novo, 2. Heterozygous LoF but status either de novo or unknown; 3. Biallelic (i.e. homozygous); 4. Putative biallelic (possibly compound heterozygous, but phasing unknown); 5. X-linked in males, maternally inherited. Data are shown in Supplementary File 1.

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

MSSNG: More than 13,000 individuals from the Autism Genetic Research Exchange (AGRE) repository and other cohorts have been whole-genome sequenced, through Autism Speaks, and data made available through the MSSNG database (https://research.mss.ng; db7 (43). MSSNG data was accessed in May 2024. SFARI: SSC biallelic: The Simons Simplex Collection (SSC) includes 2,600 simplex autism or related developmental disorder families. WES data is available for ~2,500 of these families, biallelic variants for our gene list were searched using the GPF browser (https://gpf.sfari.org/gpf19/datasets/SSC/browser). Putative compound heterozygous variants criteria for minor allele frequency (MAF) in SSC exome, gnomAD exome and genome frequencies, of <0.001, or, for missense variants, MCP scores >1 and CADD scores >18. SVIP biallelic: the autism Simons Variation in Individuals Project (SVIP) dataset was searched for putative biallelic variants through the browser gpf.sfari.org/gpf19/datasets/SVIP/browser. Putative compound heterozygous variants checked for criteria including minor allele frequency (MAF) in SSC exome, gnomAD exome and genome frequencies, of <0.001, or, for missense variants, MCP scores >1 and CADD scores >18. Deciphering Developmental Disorders (DDD) study: includes sequence data for ~14,000 children; this dataset was searched for variants in genes overlapping with our study through the known developmental genes list (https://decipher.sanger.ac.uk/ddd#ddgenes), as well as the list of research variants (https://decipher.sanger.ac.uk/ddd#research-variants), which are 2,723 variants of unknown significance from 4,293 children. For de novo variants, all are constitutive, unless specifically noted as mosaic here. CNV variants are not included here.

Autism Sequencing Consortium (ASC): genes with *de novo* variants, either in the control set or case set, from ASC exome analysis browser (https://asc.broadinstitute.org/). This dataset lists numbers of *de novo* protein-truncating variants, as well as *de novo* missense variants with MCP scores either 1-2 or ≥2. The ASC dataset includes 6,430 probands, and includes the SSC data.

DeRubeis: genes with *de novo* variants reported in the DeRubeis et al, 2014 study, with either LoF or missense variants (44). As subject IDs were not reported, overlap with other studies recorded here is not possible.

AutismKB: additional studies where variants have been reported for the genes are taken from

the Autism Knowledge Base (http://db.cbi.pku.edu.cn/autismkb v2/quick search.php), (45).

## **Neuroanatomical Enrichment Analysis**

The Allen Adult Human Brain Atlas (46), Brainspan (47), and a single-cell atlas of the mouse nervous system (48) were used to test for neuroanatomically specific expression. For each gene, expression was standardized across regions or cell types. For these compartments, each gene was then ranked from most specific to most depleted. The area under the receiver operating statistic (AUC) was used to quantify specific expression for the genes of interest within a region or cell cluster. The Mann-Whitney U test was used to test statistical significance, and the Benjamini–Hochberg procedure (49) was used to correct for multiple tests. In addition, in order to explore whether our candidate genes may contribute to electrophysiological and morphological phenotypes in neurons we cross-referenced gene expression correlates with electrophysiological phenotypes through a dataset published by Bomkamp et al, 2019 (50).

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

Results We ascertained, phenotyped, collect blood and/or saliva for DNA extraction, and performed whole exome sequencing (mean depth: 27.29; average % coverage at 30X=31.01; average % coverage at 100X=7.32; see Supplementary File 1) from 115 ASD proband (91M:24F)/mother/father trios (62 from Pakistan, 40 from Iran, and 13 from Saudi Arabia), for a total of 345 subjects (Table1). In addition, microarrays were run on 104 of the ASD probands, providing data for CNV and ROH analyses. Whole Exome Sequencing: We discovered 84 SNVs or indels through our analysis pipeline, including 49 homozygous autosomal variants, 20 autosomal de novo (and 1 inherited) variants, and 5 de novo and 9 maternally inherited X-linked variants. Biallelic mutations (Table 2): We identified homozygous variants (7 LoF or pLoF; 9 nonsynonymous; 1 in-frame del) in 17 genes that have been previously reported to be associated with autosomal recessive non-syndromic ID, including BTN3A2 (30), CC2D1A (MIM 608443; MRT3; (51)), LINS1 (28), MADD (30), MTHFR (29), RSRC1 (52,53), TECPR2 (30) and ZNF335 (27), or for syndromic or metabolic forms of autosomal recessive ID, including AGA (aspartylglucosaminuria), ASL (arginosuccinic aciduria), ASPA (aspartoacylase deficiency/Canavan disease), and HTRA2 (3-methylglutaconic aciduria). Three genes, CC2D1A, DEAF1, and VPS13B have also previously been associated with ASD or autistic features (94–96; (57)). Biallelic mutations in *DEAF1* are known to cause neurodevelopmental disorder with hypotonia, impaired expressive language, with or without seizures (MIM 617171). LoF variants were reported for new candidate genes ENPEP, DAGLA, FAXDC2, GIMAP8, HRNR, ILDR2,

SLC36A1, SCN10A, VPS16, ZNF766, and pLoF (such as canonical splice site variants) in CNPY4, DENND1B, LRRC34, PKD1L1, and PPP1R36. VPS16 has previously been reported for autosomal dominant dystonia (MIM 608559), and PKD1L1 for AR visceral heterotaxy 8 (MIM 617205). Heterozygous missense and LoF mutations in SHH are known to be involved in autosomal dominant holoprosencephaly 3 (HPE3; MIM 142945), and so it is somewhat surprising to find a homozygous missense variant associated with a milder phenotype and with no obvious HPE3-related dysmorphic features. The Asn69Ile variant in SHH substitutes an asparagine for isoleucine at a residue that is conserved across vertebrates, is predicted to be damaging, and is found in heterozygous form in only 21 out of 1.6E6 gnomAD (v4.1.0) alleles, and no homozygotes.

In one trio (trio SMPA21) we report a homozygous stop-gain variant in *DAGLA*, for which rare heterozygous variants were reported to be associated with neurodevelopmental disorders, including autism (58). SFARI also lists this as a strong candidate for a ASD disease gene (gene score of 2; <a href="https://gene.sfari.org/">https://gene.sfari.org/</a>). We also report homozygous missense variants in novel candidate genes *ANO10*, *CABP2*, *CAPSL*, *CLCA4*, *CPM*, *DNAH8*, *ERMP1*, *KSR2*, *RANBP9*, *RASAL2*, *TMEM25*, *TRIM3*, *VPS16*, and *WDR90*, plus in *SGSM3* and *EPHB1*, for which *de novo* variants in have been reported for ASD (59), and are listed respectively as strong candidate and suggestive evidence in SFARI (scores of 2 and 3, respectively).

Although not focused on consanguineous populations, WGS data from the MSSNG study, as well as WES studies such as DDD and SFARI, support a number of our candidate AR genes (see Supplementary File 1), with homozygous rare variants in *DNAH7* (MSSNG), *DNAH8* 

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

(MSSNG), CAPSL (MSSNG), and CYP2A7 (MSSNG), and putative compound heterozygous damaging rare variants in DNAH8 (in three MSSNG individuals), SCN10A (DDD), and WDR90 (DDD)(see Supplementary File 1). There was also evidence of disease-causing biallelic variants in known AR neurodevelopmental genes MTHFR (three homozygous; DDD), AGA (one homozygous stop gain; DDD), DEAF1 (two homozygous stop gain; MSSNG and DDD), ZNF335 (one homozygous missense, DDD; one putative compound heterozygous, DDD), ASL (one homozygous missense; MSSNG), CC2D1A (one homozygous missense, MSSNG; two homozygous LoF DDD), and *VPS13B* (six homozygous, nine putative compound heterozygous). De novo mutations (Table 3 & 4): De novo dominant mutations have been shown to be a major causal factor in ASD etiology. We identified 25 de novo variants (20 autosomal and 5 X-linked). Among these genes, variants in four of them have been identified in previous studies (MECP2, MYT1L, SCN2A, ZNF292). 14 of the 25 variants were LoF, three were putative LoF (splice site), and the remainder were nonsynonymous. The mutations include genes that have been implicated in other recent studies of ASD and/or ID. For instance, we report a de novo hemizygous nonsynonymous mutation in CLTRN (on chromosome X). Hemizygous mutations in CLTRN have recently been reported in several males with neutral aminoaciduria accompanied with autistic features, anxiety, depression, compulsions and motor tics (60)- a clinical picture reminiscent of the autosomal recessive Hartnup disorder (MIM 234500). There were also several other genes with de novo variants that have not been associated with ASD (or ID) previously, and may represent novel putative genes for ASD, and for other trios there are

variants in genes linked with other nervous system disorders, such as *DRP2* in Charcot-Marie-Tooth disease (61).

Our study identified a *de novo* LoF mutation in *ZNF292* (NM\_015021:c.6159\_6160del; p.Glu2054Lysfs\*14) in two trios (IAU-65 (Iranian) and Autism-10 (Pakistani)). These two trios and 26 additional families (from multiple studies and cohorts) with mutations in *ZNF292* were reported recently (62).

Cross-referencing with other datasets, there was also support for new candidate dominant/de novo autosomal genes, including ECM1, SLAMF7, NCL, FAM53C, ADGRF2, TANGO2, DGKZ, ATP2B1 (5 individuals), CBFA2T3, RETN, and PPIL2 (see Supplementary File 1). There was support for X-linked recessive (in males, maternally inherited or de novo) candidate gene NRK (three individuals), MAGEB2 (three individuals), MAGEC1 (11 individuals), MSN (five individuals), and ZNF185 (one individuals).

**X-linked (inherited; Table 4):** Two mutations were identified in well-established ASD or ID genes, namely, *AIFM1* (Cowchock syndrome; MIM 310490), and *MID2* (XLID101: MIM 300928).

## **Splice site variants**

In addition to the detection of variants at canonical splice donor and splice acceptor sites (Tables 2-4), use of SpliceAI suggests that, for the biallelic nonsynonymous variant in the known ASD/ID gene *ASL* (trio SA7), an alternative explanation could be the generation of an alternative splice donor by the cytosine to thymine transition at this site. However, other splice algorithms

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

such as <a href="https://www.fruitfly.org/seq\_tools/splice.html">https://www.fruitfly.org/seq\_tools/splice.html</a> do not support this, and molecular experimental procedures may be needed to corroborate or refute this prediction.

## Copy Number Variants (Table 5 & 6)

Eight autosomal biallelic loss CNVs were identified among five trios using microarray data, that were subsequently validated through inspection of the WES data using IGV, and through molecular methods, using PCR and/or Sanger sequencing. Of these implicated genes, mutations/knock-outs of both DHRS4 and KLK15 have a neurobehavioral phenotype in mouse models (Supplementary File 1). DNAH7 is highly expressed in brain, and both SHPK (sedoheptulokinase) and WDR73 have high expression in cerebellum. Of the biallelic CNVs identified, WDR73 has previously been associated with the autosomal recessive Galloway-Mowat syndrome 1 (MIM 251300), which includes microcephaly, delayed psychomotor development and cerebellar atrophy. Determining the ASD causative genetic variation in many of the probands with CNVs is difficult. The proband with the WRD73, CYP2A7, and KLK15 CNVs (trio IABB14) also has a biallelic splice mutation in the Canavan disease gene ASPA. Additionally, the proband with the SHPK CNV (trio IABB2) also has a biallelic LoF mutation in the known ID gene DEAF1, and the proband with the SIRPB1 CNV (trio IAU79) has a biallelic non-frameshift deletion in the known ID/spastic paraplegia gene B4GALNT1, complicating identification of the molecular causation (see Supplementary File 1). A biallelic CNV loss implicates the gene SEMG1 in trio SMPA4, however expression of this gene is restricted to the seminal vesicle (see Supplementary File 1), and thus unlikely to be related to the ASD phenotype.

There are also three large, multi-genic *de novo* CNV losses among the trios, which may also be pathogenic (Supplementary Table S1).

## **Neuroanatomical Enrichment Analysis**

Testing for regional and cell-type specific expression did not indicate clear anatomical targets with higher expression of the candidate genes. Enrichment in the cerebellum and cerebral cortex was observed in the BrainSpan human developmental atlas, but this was not supported by either the mouse or adult human atlases. We found no consistent neuroanatomical expression pattern for the identified genes, suggesting heterogeneity of neural circuits disrupted.

## High consanguinity coefficient correlates with identification of biallelic variants

Using microarray data we calculated the consanguinity coefficient  $F_{ROH}$  using autosomal RoH for 104 of the 115 trios. This included 13 trios for which LoH scores were converted to  $F_{ROH}$  using the equation  $F_{ROH}$ =(LoH - 0.0111)/1.034 (see Methods and Supplementary Materials). Comparison of the degree of consanguinity (using  $F_{ROH}$ ) between 33 trios with biallelic variants versus 20 trios with *de novo* and X-linked variants indicated a strongly significant shift (unpaired t test (two-tailed): p < 0.0001; df=51; mean  $F_{ROH}$  for biallelic variants= 0.09003, S.E.M.=0.00672, N=33; mean  $F_{ROH}$  for autosomal *de novo* and X-linked = 0.02955, S.E.M. = 0.00737, N=20). This is also true for variants identified in known ASD/ID genes (p =0.0045; df=22; mean  $F_{ROH}$  for biallelic 0.08146, N=13, S.E.M.=0.01019; mean  $F_{ROH}$  for autosomal *de novo* and X-linked = 0.03282, N=11, S.E.M.=0.01159).(Figure 2A). Comparison also showed clear differences in  $F_{ROH}$  levels between different cohorts, and country of ascertainment (Figure 2B & C).

Discussion

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

Many recent studies involving NGS in ASD have involved large cohorts, focusing predominantly on dominant/de novo inheritance. This focus is largely driven by the fact that autosomal recessive variants in novel genes are more difficult to identify in the outbred population. Identification of candidate AR ASD genes through the study of consanguineous families should help streamline the identification of biallelic mutations through clinical genetic screening in outbred populations. Using whole exome trio analysis in consanguineous families, we have enriched for recessive variants to assess the role these variants play in ASD in populations where endogamy is common. This study of 115 trios has identified WES variants for 32 trios in genes previously associated with ASD or other neurodevelopmental disorders, resulting in a diagnostic yield of 28% (18 autosomal recessive, seven autosomal de novo plus one maternally inherited, and six X-linked variants in known genes). With a further three trios with large, multigenic, loss CNVs validated experimentally as de novo and putatively pathogenic (Table 6), this yield increases to 30%. There were many other variants identified that met filtering criteria which could potentially represent novel ASD genes or targets. We present 32 new candidate autosomal recessive variants/genes, including a biallelic variant in SHH, a gene associated with autosomal dominant holoprosencephaly. Within this cohort we identified variants in five genes that are associated with known metabolic syndromes (4.3% of the diagnosis cohort): AGA, ASL, HTRA2, ASPA, and MTHFR. These genes may represent better clinical management opportunities for patients, and potentially better therapies.

A number of the known ID genes identified among the 115 ASD trios have also previously been reported for ASD or ASD-like features, e.g. *CC2D1A* (55,62,63), *VPS13B* (33), *DEAF1* (54), *ZNF335* (64), *ZNF292* (65,66), *MYT1L* (66,67), and *SCN2A* (59,68,69). Of the candidate genes identified here, MSSNG, SFARI, and other datasets provide putative support for the biallelic genes, with homozygous variants in *DNAH7*, *ANO10*, *DNAH8*, *CAPSL*, *CYP2A7*, and *SIRPB1*, and putative compound heterozygous variants in *DNAH7*, *DNAH8*, *SCN10A*, and *WDR90*, and for *de novo*/dominant genes *NCL*, *SLAMF7*, *ADGRF2*, *DGKZ*, *ATP2B1*, *CBFA2T3*, *RETN*, and *PPIL2* (Supplementary File 1).

For three of the known ASD or ID genes reported here, namely *ZNF292*, *SCN2A*, and *MECP2*, mutations have been identified in two unrelated trios from our cohort. Mutations in the known ASD gene *SCN2A* (68) were identified in two trios- both *de novo*. In addition, mutations were identified in three other voltage-gated sodium channel members, including a biallelic stop gain mutation in *SCN10A*, in which heterozygous gain of function missense mutations have previously been linked to familial episodic pain syndrome 2 (FEPS2; MIM 615551)(70), as well as *de novo* missense mutations in *SCN5A* and *SCN8A*. The *SCN8A* variant is predicted as damaging by all algorithms tested, and mutations in this gene have previously been linked to AD developmental and epileptic encephalopathy 13 (DEE13; MIM 614558). The *SCN5A* variant was predicted as benign by several of the algorithms and is less likely to be related to ASD in this trio. The Arg267\* mutation identified in *MECP2* in trio SMPA78 has been frequently reported in cases of Rett syndrome. However more C-terminal truncating mutations such as the Thr412Asnfs\*5 mutation in trio IAU54 typically have a significantly milder phenotype(71).

For some of the autosomal recessive candidate genes, there is additional support from animal models. For instance, *Rasal2* (MGI:2443881) and *Vps1*6 (MGI:2136772) knockout mice have behavioral/neurological and nervous system phenotypes (http://www.informatics.jax.org/; Supplementary File 1). Additional discussion of mouse models relevant to the candidate genes is provided in Supplementary Materials.

There are several trios for which there are two or more candidate variants (Supplementary File 1). For some of these, there may be a variant that clearly delivers a more plausible etiopathological explanation. For instance, for trio SMPA3 the biallelic change in *MTHFR*; for trio IAH2, the biallelic LoF change in *TECPR2* (SPG49; MIM 615031; ID (30); hereditary sensory neuropathy with ID (72)); for trio IABB2, the biallelic LoF variant in (NEDHELS; MIM 617171); for trio IABB14, the biallelic splice mutation in ASPA (Canavan disease; MIM 271900).

Since our initial methodology used relatively stringent MAF cut-off criteria for biallelic variants (<0.001), we attempted to justify this level by reiterating the analysis but with lower thresholds (<0.01). Using the more relaxed criteria resulted in just two additional candidate variants, in the genes *CLCA4* (gnomAD South Asian MAF=1.72E-3), and *RASAL2* (gnomAD South Asian MAF=6E-3), but none in known neurodevelopmental genes. Our methodology was particularly stringent regarding *de novo* nonsynonymous variants, owing to the large number of likely spurious calls, and the inclusion of only variants predicted as damaging by all algorithms used may have excluded some *bona fide* mutations. Other variants, particularly intronic or intergenic, would also likely be missed by our approach. Also, a proportion of exons, and particularly in GC-rich regions, are either missed or have low coverage in WES. Follow-up with

whole genome sequencing could be considered as a possible next step. However, parsing and assessing rare non-coding variants is particularly challenging.

It was recently estimated in the DDD cohort that recessive variants make up 3.6% of diagnoses, whereas *de novo* variants contribute 48.6% of variants (38). The same study also compared homozygous variants in a narrowly defined group of Pakistani Ancestry in the British Isles (PABI), which is most like our cohort (38). The PABI cohort had 356 (333 undiagnosed) probands, 110 of whom (30.9%) had biallelic coding candidate variants, approximately half of which are in known DD genes and half in novel candidates (38). For comparison, our study reports very similar yields for recessive variants, with 15% of probands with biallelic variants in known ASD/ID genes (17/115), or 30% including those with biallelic variants in novel candidate genes (35/115). We report 28 *de novo* variants (20 autosomal, five X-linked, three CNVs) in 17 of 115 individuals (15%), which is somewhat lower than those reported for the PABI cohort (29.8%). This difference is most likely due to differences in the methodologies or stringency used for calling *de novo* variants in the respective studies.

Comparison of consanguinity ( $F_{ROH}$ ) between trios with biallelic variants (either known or candidates) versus trios with *de novo* and X-linked variants indicated a strongly significant shift.. Thus, unsurprisingly, the chances of finding biallelic rare variants is strongly associated with higher consanguinity, and should be a consideration for diagnostic genetic analysis.

Overall, the findings demonstrate the importance of autosomal recessive mutations in ASD in countries, or in cohorts, with high rates of consanguinity. In countries where consanguinity is rare, when screening ASD individuals' genomes attention should still be paid to

the relatedness of the parents, and, for those with a high F-coefficient, attention should be focused on biallelic variants. Additionally, the candidate genes reported here should be examined for both autozygous *and* allozygous mutations in outbred populations, just as would be done for more established autosomal recessive gene disorders.

## **Declaration of Interests Statement**

L.F. owns shares in Quince Therapeutics and has received consulting fees from PeopleBio Co., GC

Therapeutics Inc., Cortexyme Inc., and Keystone Bio. M.A. is co-founder and director of Institute of

Omics and Health Research, Lahore, a research organization. The organization was not involved

in the research on which this manuscript is based. All other authors declare no competing

interests.

## **Acknowledgements**

The authors thank the families for their participation in this study. We acknowledge the assistance of Natalie Freeman with PLINK microarray analysis, and of Stephen Pastore with the preparation of violin plots using R software. This work was supported by grants from the Canadian Institutes of Health Research to JBV (#MOP-102758 and #PJT-156402), also a Brain & Behavior Research Foundation (BBRF/NARSAD) Young Investigator Award to NV. RH was supported by a Peterborough K.M. Hunter Charitable Foundation Graduate Scholarship. AR and AH were supported by International Research Fellowship Program scholarships from the

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

Pakistani Higher Education Commission. CS was supported by a Summer University Research Program award from the Institute of Medical Science, University of Toronto. Computations were performed on the CAMH Specialized Computing Cluster. The SCC is funded by The Canada Foundation for Innovation, Research Hospital Fund. Additional acknowledgements are included in Supplementary Materials Data and code availability New variants reported here are available through ClinVar SUB14665852, and SCV accession numbers are included in Supplementary File 1. Microarray genotype data and whole exome sequence data will be made available from the corresponding author upon request. References 1. Helt M, Kelley E, Kinsbourne M, Pandey J, Boorstein H, Herbert M, et al. Can children with autism recover? If so, how? Neuropsychol Rev. 2008 Dec;18(4):339-66. 2. Mason D, Capp SJ, Stewart GR, Kempton MJ, Glaser K, Howlin P, et al. A Meta-analysis of Outcome Studies of Autistic Adults: Quantifying Effect Size, Quality, and Meta-regression. J

464 3. Lai MC, Kassee C, Besney R, Bonato S, Hull L, Mandy W, et al. Prevalence of co-occurring mental health diagnoses in the autism population: a systematic review and meta-analysis.

466 Lancet Psychiatry. 2019 Oct;6(10):819–29.

Autism Dev Disord. 2021 Sep;51(9):3165–79.

- 4. Baxter AJ, Brugha TS, Erskine HE, Scheurer RW, Vos T, Scott JG. The epidemiology and global burden of autism spectrum disorders. Psychol Med. 2015 Feb;45(3):601–13.
- 5. Elsabbagh M, Divan G, Koh YJ, Kim YS, Kauchali S, Marcín C, et al. Global Prevalence of Autism and Other Pervasive Developmental Disorders. Autism Res. 2012 Jun;5(3):160–79.
- Baird G, Simonoff E, Pickles A, Chandler S, Loucas T, Meldrum D, et al. Prevalence of disorders of the autism spectrum in a population cohort of children in South Thames: the Special Needs and Autism Project (SNAP). Lancet Lond Engl. 2006 Jul 15;368(9531):210–5.

- 7. Developmental Disabilities Monitoring Network Surveillance Year 2010 Principal
- 476 Investigators, Centers for Disease Control and Prevention (CDC). Prevalence of autism
- spectrum disorder among children aged 8 years autism and developmental disabilities
- 478 monitoring network, 11 sites, United States, 2010. Morb Mortal Wkly Rep Surveill Summ
- 479 Wash DC 2002. 2014 Mar 28;63(2):1–21.
- 480 8. Kim YS, Leventhal BL, Koh YJ, Fombonne E, Laska E, Lim EC, et al. Prevalence of autism spectrum disorders in a total population sample. Am J Psychiatry. 2011 Sep;168(9):904–12.
- 482 9. Lundström S, Reichenberg A, Anckarsäter H, Lichtenstein P, Gillberg C. Autism phenotype versus registered diagnosis in Swedish children: prevalence trends over 10 years in general
- population samples. BMJ. 2015 Apr 28;350:h1961.
- 485 10. Maenner MJ. Prevalence of Autism Spectrum Disorder Among Children Aged 8 Years —
- Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2016.
- 487 MMWR Surveill Summ [Internet]. 2020 [cited 2021 Jun 5];69. Available from:
- https://www.cdc.gov/mmwr/volumes/69/ss/ss6904a1.htm
- 489 11. Maenner MJ. Prevalence and Characteristics of Autism Spectrum Disorder Among Children
- 490 Aged 8 Years Autism and Developmental Disabilities Monitoring Network, 11 Sites,
- United States, 2020. MMWR Surveill Summ [Internet]. 2023 [cited 2024 Sep 16];72.
- 492 Available from: https://www.cdc.gov/mmwr/volumes/72/ss/ss7202a1.htm
- 12. Fombonne E. Editorial: The rising prevalence of autism. J Child Psychol Psychiatry.
- 494 2018;59(7):717–20.
- 495 13. Hansen SN, Schendel DE, Parner ET. Explaining the increase in the prevalence of autism
- spectrum disorders: the proportion attributable to changes in reporting practices. JAMA
- 497 Pediatr. 2015 Jan;169(1):56–62.
- 498 14. Lord C, Brugha T, Charman T, Cusack J, Dumas G, Frazier T, et al. Autism spectrum disorder. Nat Rev Dis Primer. 2020 Jan 16;6(1):5.
- 500 15. Rødgaard EM, Jensen K, Vergnes JN, Soulières I, Mottron L. Temporal Changes in Effect
- Sizes of Studies Comparing Individuals With and Without Autism: A Meta-analysis. JAMA
- 502 Psychiatry. 2019 Nov 1;76(11):1124–32.
- 16. Hossain MD, Ahmed HU, Jalal Uddin MM, Chowdhury WA, Iqbal MS, Kabir RI, et al.
- Autism Spectrum disorders (ASD) in South Asia: a systematic review. BMC Psychiatry.
- 505 2017 Aug 1;17(1):281.
- 506 17. Imran N, Bhatti MR, Anwar A, Najmi F, Haider II. Children's Mental Health: Pattern of
- referral, distribution of disorders and service use in child psychiatry outpatient setting. Pak J
- 508 Med Sci. 2012;28(1):22–6.
- 18. Syed EU, Hussein SA, Yousafzai AW. Developing Services with Limited Resources:
- Establishing a CAMHS in Pakistan. Child Adolesc Ment Health. 2007;12(3):121–4.

- 19. Tareen A, Mirza I, Minhas A, Minhas F, Rahman A. Developing a child and adolescent
- mental health service in a low-income country: a global partnership model. Psychiatr Bull.
- 513 2009 May;33(5):181–3.
- 26. Sarwat A, Ali SMI, Ejaz MS. Mental health comorbidity in children: a hospital based study
- in child psychiatry clinic. Pak J Med Sci. 2009;25(6):982–5.
- 516 21. Minhas A, Vajaratkar V, Divan G, Hamdani SU, Leadbitter K, Taylor C, et al. Parents'
- 517 perspectives on care of children with autistic spectrum disorder in South Asia Views from
- Pakistan and India. Int Rev Psychiatry. 2015 May 4;27(3):247–56.
- 519 22. Rauf NK, Anis-ul-Haq null, Aslam N, Anjum U. Characteristic symptoms and adaptive
- behaviors of children with autism. J Coll Physicians Surg--Pak JCPSP. 2014 Sep;24(9):658–
- 521 62.
- 522 23. Bundey S, Alam H. A five-year prospective study of the health of children in different ethnic
- groups, with particular reference to the effect of inbreeding. Eur J Hum Genet EJHG.
- 524 1993;1(3):206–19.
- 525 24. Modell B, Darr A. Science and society: genetic counselling and customary consanguineous
- 526 marriage. Nat Rev Genet. 2002 Mar;3(3):225–9.
- 527 25. Harripaul R, Vasli N, Mikhailov A, Rafiq MA, Mittal K, Windpassinger C, et al. Mapping
- autosomal recessive intellectual disability: combined microarray and exome sequencing
- identifies 26 novel candidate genes in 192 consanguineous families. Mol Psychiatry.
- 530 2018;23(4):973–84.
- 531 26. Riazuddin S, Hussain M, Razzaq A, Iqbal Z, Shahzad M, Polla DL, et al. Exome sequencing
- of Pakistani consanguineous families identifies 30 novel candidate genes for recessive
- intellectual disability. Mol Psychiatry. 2017 Nov;22(11):1604–14.
- 534 27. Hu H, Kahrizi K, Musante L, Fattahi Z, Herwig R, Hosseini M, et al. Genetics of intellectual
- disability in consanguineous families. Mol Psychiatry. 2018 Jan 4;
- 536 28. Najmabadi H, Hu H, Garshasbi M, Zemojtel T, Abedini SS, Chen W, et al. Deep sequencing
- reveals 50 novel genes for recessive cognitive disorders. Nature. 2011 Sep 21;478(7367):57–
- 538 63.
- 29. Reuter MS, Tawamie H, Buchert R, Hosny Gebril O, Froukh T, Thiel C, et al. Diagnostic
- Yield and Novel Candidate Genes by Exome Sequencing in 152 Consanguineous Families
- With Neurodevelopmental Disorders. JAMA Psychiatry. 2017 Mar 1;74(3):293–9.
- 30. Anazi S, Maddirevula S, Salpietro V, Asi YT, Alsahli S, Alhashem A, et al. Expanding the
- genetic heterogeneity of intellectual disability. Hum Genet. 2017 Nov;136(11–12):1419–29.
- 31. Morrow EM, Yoo SY, Flavell SW, Kim TK, Lin Y, Hill RS, et al. Identifying autism loci
- and genes by tracing recent shared ancestry. Science. 2008 Jul 11;321(5886):218–23.

- 32. Al-Mubarak B, Abouelhoda M, Omar A, AlDhalaan H, Aldosari M, Nester M, et al. Whole
- exome sequencing reveals inherited and de novo variants in autism spectrum disorder: a trio
- study from Saudi families. Sci Rep. 2017 Jul 18;7(1):5679.
- 33. Yu TW, Chahrour MH, Coulter ME, Jiralerspong S, Okamura-Ikeda K, Ataman B, et al.
- Using whole-exome sequencing to identify inherited causes of autism. Neuron. 2013 Jan
- 551 23;77(2):259–73.
- 34. Mamidala MP, Kalikiri MK, Praveen Kumar PTV, Rajesh N, Vallamkonda OR, Rajesh V.
- Consanguinity in India and its association with autism spectrum disorder. Autism Res Off J
- Int Soc Autism Res. 2015 Apr;8(2):224–8.
- 35. Lim ET, Raychaudhuri S, Sanders SJ, Stevens C, Sabo A, MacArthur DG, et al. Rare
- complete knockouts in humans: population distribution and significant role in autism
- spectrum disorders. Neuron. 2013 Jan 23;77(2):235–42.
- 36. Howrigan DP, Simonson MA, Davies G, Harris SE, Tenesa A, Starr JM, et al. Genome-wide
- autozygosity is associated with lower general cognitive ability. Mol Psychiatry.
- 560 2016;21(6):837–43.
- 37. Kaiser VB, Svinti V, Prendergast JG, Chau YY, Campbell A, Patarcic I, et al. Homozygous
- loss-of-function variants in European cosmopolitan and isolate populations. Hum Mol Genet.
- 563 2015 Oct 1;24(19):5464–74.
- 38. Martin HC, Jones WD, McIntyre R, Sanchez-Andrade G, Sanderson M, Stephenson JD, et
- al. Quantifying the contribution of recessive coding variation to developmental disorders.
- 566 Science. 2018 07;362(6419):1161–4.
- 39. Kahrizi K, Hu H, Hosseini M, Kalscheuer VM, Fattahi Z, Beheshtian M, et al. Effect of
- inbreeding on intellectual disability revisited by trio sequencing. Clin Genet.
- 569 2019;95(1):151–9.
- 570 40. Ramaswami G, Geschwind DH. Genetics of autism spectrum disorder. Handb Clin Neurol.
- 571 2018;147:321–9.
- 41. McQuillan R, Leutenegger AL, Abdel-Rahman R, Franklin CS, Pericic M, Barac-Lauc L, et
- al. Runs of homozygosity in European populations. Am J Hum Genet. 2008 Sep;83(3):359–
- 574 72.
- 42. Robinson JT, Thorvaldsdóttir H, Winckler W, Guttman M, Lander ES, Getz G, et al.
- Integrative genomics viewer. Nat Biotechnol. 2011 Jan;29(1):24–6.
- 577 43. Yuen RKC, Merico D, Cao H, Pellecchia G, Alipanahi B, Thiruvahindrapuram B, et al.
- Genome-wide characteristics ofde novomutations in autism. NPJ Genomic Med. 2016 Aug
- 579 3;1:160271–1602710.
- 580 44. De Rubeis S, He X, Goldberg AP, Poultney CS, Samocha K, Cicek AE, et al. Synaptic,
- transcriptional and chromatin genes disrupted in autism. Nature. 2014 Nov
- 582 13;515(7526):209–15.

- 583 45. Yang C, Li J, Wu Q, Yang X, Huang AY, Zhang J, et al. AutismKB 2.0: a knowledgebase
- for the genetic evidence of autism spectrum disorder. Database J Biol Databases Curation.
- 585 2018 Jan 1;2018.
- 586 46. Hawrylycz MJ, Lein ES, Guillozet-Bongaarts AL, Shen EH, Ng L, Miller JA, et al. An
- anatomically comprehensive atlas of the adult human brain transcriptome. Nature. 2012 Sep
- 588 20;489(7416):391–9.
- 589 47. Li M, Santpere G, Imamura Kawasawa Y, Evgrafov OV, Gulden FO, Pochareddy S, et al.
- Integrative functional genomic analysis of human brain development and neuropsychiatric
- risks. Science. 2018 14;362(6420).
- 592 48. Zeisel A, Hochgerner H, Lönnerberg P, Johnsson A, Memic F, van der Zwan J, et al.
- Molecular Architecture of the Mouse Nervous System. Cell. 2018 Aug 9;174(4):999-
- 594 1014.e22.
- 595 49. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful
- Approach to Multiple Testing. J R Stat Soc Ser B Methodol. 1995 Jan;57(1):289–300.
- 50. Bomkamp C, Tripathy SJ, Bengtsson Gonzales C, Hjerling-Leffler J, Craig AM, Pavlidis P.
- 598 Transcriptomic correlates of electrophysiological and morphological diversity within and
- across excitatory and inhibitory neuron classes. PLoS Comput Biol. 2019
- 600 Jun;15(6):e1007113.
- 51. Basel-Vanagaite L, Attia R, Yahav M, Ferland RJ, Anteki L, Walsh CA, et al. The CC2D1A.
- a member of a new gene family with C2 domains, is involved in autosomal recessive non-
- syndromic mental retardation. J Med Genet. 2006 Mar;43(3):203–10.
- 52. Perez Y, Menascu S, Cohen I, Kadir R, Basha O, Shorer Z, et al. RSRC1 mutation affects
- intellect and behaviour through aberrant splicing and transcription, downregulating IGFBP3.
- 606 Brain J Neurol. 2018 Apr 1;141(4):961–70.
- 53. Maddirevula S, AlZahrani F, Anazi S, Almureikhi M, Ben-Omran T, Abdel-Salam GMH, et
- al. GWAS signals revisited using human knockouts. Genet Med Off J Am Coll Med Genet.
- 609 2018 Jan;20(1):64–8.
- 54. Nabais Sá MJ, Jensik PJ, McGee SR, Parker MJ, Lahiri N, McNeil EP, et al. De novo and
- biallelic DEAF1 variants cause a phenotypic spectrum. Genet Med Off J Am Coll Med
- Genet. 2019 Sep;21(9):2059–69.
- 55. Manzini MC, Xiong L, Shaheen R, Tambunan DE, Di Costanzo S, Mitisalis V, et al.
- 614 CC2D1A regulates human intellectual and social function as well as NF-κB signaling
- 615 homeostasis. Cell Rep. 2014 Aug 7;8(3):647–55.
- 56. Douzgou S, Petersen MB. Clinical variability of genetic isolates of Cohen syndrome. Clin
- 617 Genet. 2011 Jun;79(6):501–6.

- 57. Rajab A, Schuelke M, Gill E, Zwirner A, Seifert F, Morales Gonzalez S, et al. Recessive
- DEAF1 mutation associates with autism, intellectual disability, basal ganglia dysfunction
- and epilepsy. J Med Genet. 2015 Sep;52(9):607–11.
- 58. Smith DR, Stanley CM, Foss T, Boles RG, McKernan K. Rare genetic variants in the
- endocannabinoid system genes CNR1 and DAGLA are associated with neurological
- phenotypes in humans. PloS One. 2017;12(11):e0187926.
- 59. Sanders SJ, Murtha MT, Gupta AR, Murdoch JD, Raubeson MJ, Willsey AJ, et al. De novo
- mutations revealed by whole-exome sequencing are strongly associated with autism. Nature.
- 626 2012 Apr 4;485(7397):237–41.
- 627 60. Pillai NR, Yubero D, Shayota BJ, Oyarzábal A, Ghosh R, Sun Q, et al. Loss of CLTRN
- function produces a neuropsychiatric disorder and a biochemical phenotype that mimics
- Hartnup disease. Am J Med Genet A. 2019 Dec;179(12):2459–68.
- 630 61. Berciano J, García A, Gallardo E, Peeters K, Pelayo-Negro AL, Álvarez-Paradelo S, et al.
- Intermediate Charcot-Marie-Tooth disease: an electrophysiological reappraisal and
- 632 systematic review. J Neurol. 2017 Aug;264(8):1655–77.
- 633 62. Mirzaa GM, Chong JX, Piton A, Popp B, Foss K, Guo H, et al. De novo and inherited
- variants in ZNF292 underlie a neurodevelopmental disorder with features of autism spectrum
- disorder. Genet Med. 2020 Mar;22(3):538–46.
- 63. Sener EF, Onal MG, Dal F, Nalbantoglu U, Ozkul Y, Canatan H, et al. Novel alterations of
- 637 CC2D1A as a candidate gene in a Turkish sample of patients with autism spectrum disorder.
- 638 Int J Neurosci. 2020 Dec 28;1–8.
- 639 64. Wu J, Yu P, Jin X, Xu X, Li J, Li Z, et al. Genomic landscapes of Chinese sporadic autism
- spectrum disorders revealed by whole-genome sequencing. J Genet Genomics Yi Chuan Xue
- 641 Bao. 2018 Oct 20;45(10):527–38.
- 642 65. Guo H, Wang T, Wu H, Long M, Coe BP, Li H, et al. Inherited and multiple de novo
- mutations in autism/developmental delay risk genes suggest a multifactorial model. Mol
- 644 Autism. 2018;9:64.
- 66. Wang T, Guo H, Xiong B, Stessman HAF, Wu H, Coe BP, et al. De novo genic mutations
- among a Chinese autism spectrum disorder cohort. Nat Commun. 2016 Nov 8;7:13316.
- 647 67. Coursimault J, Guerrot AM, Morrow MM, Schramm C, Zamora FM, Shanmugham A, et al.
- MYT1L-associated neurodevelopmental disorder: description of 40 new cases and literature
- review of clinical and molecular aspects. Hum Genet. 2021 Nov 8;
- 650 68. Weiss LA, Escayg A, Kearney JA, Trudeau M, MacDonald BT, Mori M, et al. Sodium
- channels SCN1A, SCN2A and SCN3A in familial autism. Mol Psychiatry. 2003
- 652 Feb;8(2):186–94.

689

- 69. Jiang Y hui, Yuen RKC, Jin X, Wang M, Chen N, Wu X, et al. Detection of clinically
- relevant genetic variants in autism spectrum disorder by whole-genome sequencing. Am J
- 655 Hum Genet. 2013 Aug 8;93(2):249–63.
- 70. Faber CG, Lauria G, Merkies ISJ, Cheng X, Han C, Ahn HS, et al. Gain-of-function Nav1.8 mutations in painful neuropathy. Proc Natl Acad Sci U S A. 2012 Nov 20;109(47):19444–9.
- 71. Bebbington A, Percy A, Christodoulou J, Ravine D, Ho G, Jacoby P, et al. Updating the
   profile of C-terminal MECP2 deletions in Rett syndrome. J Med Genet. 2010
   Apr;47(4):242–8.
- 72. Neuser S, Brechmann B, Heimer G, Brösse I, Schubert S, O'Grady L, et al. Clinical, neuroimaging, and molecular spectrum of TECPR2-associated hereditary sensory and autonomic neuropathy with intellectual disability. Hum Mutat. 2021 Jun;42(6):762–76.
- 73. Schopler E, Reichler RJ, DeVellis RF, Daly K. Toward objective classification of childhood
   autism: Childhood Autism Rating Scale (CARS). J Autism Dev Disord. 1980 Mar;10(1):91–
   103.
- 74. Lord C, Rutter M, Le Couteur A. Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord. 1994 Oct;24(5):659–85.
- 75. Lord C, Rutter M, Goode S, Heemsbergen J, Jordan H, Mawhood L, et al. Autism diagnostic
   observation schedule: a standardized observation of communicative and social behavior. J
   Autism Dev Disord. 1989 Jun;19(2):185–212.
- 76. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders,
   4th Edition, Text Revision. 4th edition. Washington, DC: American Psychiatric Association;
   2000. 943 p.
- 77. Skuse D, Warrington R, Bishop D, Chowdhury U, Lau J, Mandy W, et al. The
   developmental, dimensional and diagnostic interview (3di): a novel computerized assessment
   for autism spectrum disorders. J Am Acad Child Adolesc Psychiatry. 2004 May;43(5):548–
   58.
- 78. American Psychiatric Association, American Psychiatric Association, DSM-5 Task Force.
  Diagnostic and statistical manual of mental disorders: DSM-5. [Internet]. 2013 [cited 2016
  Dec 14]. Available from: http://dsm.psychiatryonline.org/book.aspx?bookid=556
- 79. World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders
   [Internet]. World Health Organization; 2010. Available from:
   https://www.who.int/classifications/icd/en/bluebook.pdf
- 80. Packer JS, Maxwell EK, O'Dushlaine C, Lopez AE, Dewey FE, Chernomorsky R, et al. CLAMMS: a scalable algorithm for calling common and rare copy number variants from exome sequencing data. Bioinformatics. 2016 Jan 1;32(1):133–5.

690

# **Table 1:** Cohort Description and clinical assessment.

Cohort ID (Recruited By)	Institute	Nationality (Age range)	Number of Trios (Number of DNAs)	Proband Male: Female	Instruments and diagnostic system	Assessors
SMPA (Ansa Rabia, Saqib Mahmood, Shazia Maqbool)	University of Health Sciences and Children Hospital, Lahore	Pakistan	54 (162)	42:12	Childhood Autism Rating Scale (CARS)(73) DSM IV	Physicians with expertise in neurodevelopmental disorders
IAU (Dr. Sasanfar)	Children's Health and Evaluation Project/ Special Education Organization	Iran (4-11)	27 (81)	23:4	ADI-R (74) and ADOS (75) (DSM-IV-TR) (76); SCQ (50)	Certified Physicians
IABB (Dr. Bita Bozorgmehr)	Shahid Beheshti Medical University, Teheran	Iran	10 (30)	9:2	Autism Spectrum Screening Questionnaire (ref) DSM IV	Dr. Bita Bozorgmehr
SA (Laila Al Ayadhi)	Autism Treatment Centre, King Saud University, Riyadh	Saudi Arabia (2-12)	13 (39)	12:1	ADI-R (74), Autism Diagnostic Observation Schedule (ADOS) (75) and 3DI (Developmental, dimensional diagnostic interview) scales (77) Childhood Autism Rating Scale (CARS)(73); DSM IV	Laila Al Ayadhi
Autism (Raheel Qamar, Maleeha Azam and Zehra Agha)	COMSATS University, Islamabad, and National Rural Support Program	Pakistan	4 (12)	4:4	Childhood Autism Rating Scale (CARS)(73)	Who?

RQPA (Raheel Qamar, Maleeha Azam and Zehra Agha)	and the Ghazi Barotha Taraqiata iDara		4 (12		DSM-5 (78) and ICD-10 criteria (79)	Who?
IAH (Abolfazl Heidari)	Qazvin Medical University, Qazvin	Iran	3 (9)	2:1	DSM IV	Dr Hossein Mojdehipanah
Total			115 (345)	91:24		

Table 2: Biallelic/homozygous variants: Genes previously reported as pathogenic for ASD/ID or other disorder are indicated, with annotation using (in order of priority): OMIM: <a href="https://omim.org/">https://omim.org/</a>; SFARI ASD genes <a href="https://gene.sfari.org/">https://gene.sfari.org/</a>; DDD gene2phenotype genes: <a href="https://gene.sfari.org/">https://gene.sfari.org/</a>; Genes previously genes database: <a href="https://gene4denovo/">https://gene4denovo/</a>; Gene4denovo: <a href="https://gene4denovo/search">https://gene4denovo/search</a>. Genes previously unreported for ASD or ID are in bold type. Control population frequencies show are from gnomAD (all, and for South Asian sub-population). All variants were validated by IGV (Integrated Genomics Viewer; Broad Institute) and by Sanger sequencing. Validations are shown in Supplementary Materials. Allele frequencies are from gnomAD v2.1.1 (www. <a href="https://gnomad.broadinstitute.org/">https://gnomad.broadinstitute.org/</a>; accessed June 2022).

Variant	riant Family		Coordinate	Ref.	Alt.	Gene	Variant Type	cDNA/Amino Acid Change	gnomAD Al	AllgnomAD S.	
			s (hg19)						Freq.	Asian Freq.	
1	SMPA3	1	11855404	С		MTHFR (29)(MIM 236250; SFARI score 2)	nonsynonymous	NM_001330358.2: exon6: c. 905G>T: p. Gly302Val	3.99E-06	3.27E-05	
2	IABB16	1	87029377	G	A	CLCA4	nonsynonymous	NM_012128.3:c.482G>A:p.Arg161Gln	4.11E-04	1.72E-03	
3	SMPA4	1	152193673- 152193682		_	HRNR	frameshift del	NM_001009931.3: exon3: c.423_432del:p.Arg142Glufs*15	4.37E-05	3.59E-4	
4	SMPA76	1	166891855- 166891856	СТ	-	ILDR2	frameshift del	NM_199351.3: exon8: c.1187_1188del: p. Glu396Glyfs*39	3.98E-06	3.27E-05	
5	SMPA3	1	178425880	С	A	RASAL2	Nonsynonymous	NM_004841.3: exon11: c.1813C>A: p. Leu605lle	6.72E-4	6.04E-3	
6	SMPA40	1	197621364	С	A	DENND1B	Splicing	NM_001195215.1: exon7: c.447+1G>T	0	0	
7	Autism8	2	74759786	G	Т	HTRA2 (MIM 617248)	Nonsynonymous	NM_013247.3: exon7: c.1156G>T: p. Asp386Tyr	7.95E-06	6.53E-05	
8	SMPA19	3	38802185	С	A	SCN10A	Stopgain	NM_001293306.2: exon7: c.937G>T; p. Gly313*	3.98E-06	3.27E-05	
9	SMPA76	3	43593070	С		<b>ANO10</b> (spinocerebellar ataxia 10, MIM 613728)	Nonsynonymous	NM_001346463.2:exon11:c.1679G>T:p.Cys560Phe	0	0	
10	SA15	3	47164429	G		SETD2 (LLS (AD) MIM 616831; SFARI score 1; Geisinger Tier 1)	Nonsynonymous	NM_001349370.3: exon2:c.1565C>G: p. Ser522Cys	0	0	

11	SMPA27	3	134911657	Т	С	EPHB1 (SFARI score 3)	Nonsynonymous	NM_004441.3: exon11: c.2122T>C: p. Phe708Lys	4.01E-06	3.27E-05
12	Autism3	3	157840002	С	Т	RSRC1 (MRT70; MIM 618402; SFARI score S)	Stopgain	NM_001271834.2: exon2:c.109C>T: p. Arg37*	0	0
13	SMPA8	3	169524635	С	Т	LRRC34	Splicing	NM_001172779.1: exon5: c.528+1G>A	4.08E-06	03.44E-05
14	SMPA40	4	111480831	С	Т	ENPEP	Stop gain	NM_001977.4: exon19: c.2671C>T; p.Arg891*	1.791E-4	1.34E-03
15	RQPA12	4	178360822	G	А	AGA (MIM 208400)	Nonsynonymous	NM_000027.3: exon3: c.302C>T: p. Ala101Val	3.98E-06	3.27E-05
16	SMPA35	4	185033930	CAT	С	ENPP6	frameshift del	NM_153343.3: exon6: c.886_887del: p.Met296Aspfs*28	0	0
17	IABB11	5	35910583	С	Т	CAPSL	Nonsynonymous	NM_144647.3:c.200G>A:p.Gly67Glu	0	0
18	Autism8	5	150846823	-	CTGG	SLC36A1	frameshift ins	NM_001308150.2: exon6:c.487_490dup: p. Asp164Glyfs*2	8.01E-06	6.6E-05
19	IAU56	5	154199963	С	-	FAXDC2	frameshift del	NM_032385.3: exon9: c.915delG: p.Thr306Profs*100	5.28E-05	3.93E-04
20	SMPA48	6	13634723	С	G	RANBP9	Nonsynonymous	NM_005493.3: exon11: c.1735G>C: p. Gly579Arg	2.89E-05	1.06E-04
21	IABB8	6	38851674	А	Т	DNAH8	Nonsynonymous	NM_001206927.2: exon56: c.8159A>T: p. Asp2720Val	1.24E-05	1.02E-04
22	IAU7	7	47944924	Т	С	PKD1L1 (AR laterality defects; MIM 616205)	Splicing	NM_138295.3: exon11: c.1523-2A>G	0	0
23	SA7	7	65551627	С	Т	ASL (MIM 207900)#	Nonsynonymous	NM_001024943.2: exon6:c.502C>T: p. Arg168Cys	7.98E-06	0
24	IABB7	7	99720009	G	С	CNPY4	Splicing	NM_152755.1: exon2: c.245+1G>C	2.12E-05	0
25	IAU79	7	150174821	тсс	Т	GIMAP8	frameshift del	NM_175571.3: exon5: c.1952_1953del: p. Gln652Serfs*6	0	0
26	SMPA11	7	155604611	Т	А	SHH (HPE3 (AD) MIM 142945)	Nonsynonymous	NM_000193.4: exon1: c.206A>T: p. Asn69lle	2.39E-06	1.96E-4
27	IABB3	8	100155379	AG	A	VPS13B (COH1 MIM 216550; SFARI score 1; Geisinger AR)	frameshift del	NM_015243.3: exon13: c.1829delG: p. Ser610Thrfs*3	0	0
28	SA4	9	5805613	Т	С	ERMP1	Nonsynonymous	NM_024896.3: exon9: c.1721A>G: p.His574Arg	0	0
29	IABB2	11	679701	G	GA	DEAF1 (MIM 617171; SFARI score 1; Geisinger AR)	frameshift ins	NM_001293634.1: exon6: c.845dupT: p. Ala283Argfs*20	0	0

30	SMPA11	11	6477889	С	А	TRIM3	Nonsynonymous	NM_033278.3:exon6:c.1067G>T:p.Arg356Leu	0	0
31	SMPA20	11	47305749	A	G	MADD (27,30)	Nonsynonymous	NM_001135943.2: exon11: c. 1883A>G: p. Tyr628Cys	1.99E-05	1.63E-04
32	SMPA21	11	61495635	С	G	DAGLA (SFARI score 2)	Stopgain	NM_006133.3: exon7:c.647C>G: p. Ser216*	0	0
33	SMPA80	11	67290028	С	Т	CABP2 (Deafness, MIM 607314)	Nonsynonymous	NM_016366.3: exon2: c.202G>A: p. Ala68Thr	5.70E-05	3.48E-04
34	SMPA8	11	118403863	A	G	TMEM25	Nonsynonymous	NM_001144036.2: exon3: c. 302A>G: p. Asn101Ser	3.64E-05	2.62E-04
35	IAU79	12	_	GGGAAGCCGAC GAGCTCGTGGT	G	B4GALNT1 (Spastic paraplegia 26; MIM 609195 ID reported in some cases)		NM_001276468.2: exon9: c.1094_1114del: p.His365_Phe372del	0	0
36	IABB10	12	69263140	С	G	СРМ	Nonsynonymous	NM_001005502.2: exon6: c.752G>C: p. Gly251Ala	0	0
37	IABB11	12	118199039	G	А	KSR2	Nonsynonymous	NM_173598.6:exon4:c.763C>T:p.Arg255Trp	2.196E-05	0
38	SMPA8	14	65032074	G	С	PPP1R36	Splicing	NM_172365: exon5: c.270-1G>C	1.21E-05	9.99E-05
39	IAH2	14	102963429	TGTGGGGACCGC CTG	T	TECPR2 Anazi et al, 2017 PMID 27431290); Neuropathy, hereditary sensory and autonomic, type IX, with developmental delay (HSAN9): MIM 615031	frameshift del	NM_014844.3: exon18: c.3904_3917del: p. Val1302Glyfs*60	0	0
40	IABB4	15	101113962	Т	-	LINS1 (MRT27; MIM 614340; Geisinger AR)	frameshift del	NM_001040616.3: exon5: c.1116delA: p. Glu372Aspfs*9	0	0
41	SMPA76	16	716004	С	Т	WDR90	Nonsynonymous	NM_145294.4: exon36: c.4489C>T: p. Arg1497Trp	3.72E-06	8.04E-06
42	IABB14	17	3392637	G	Т	ASPA (Canavan disease; MIM 271900)	Splicing	NM_001128085: exon5: c.634+1G>T	1.06E-05	3.28E-05
43	SA2	19	14024452	G	Т	CC2D1A (MRT3; MIM 608443; SFARI score 2; Geisinger AR)	Splicing	NM_017721: exon6: c.748+1G>T	0	0
44	IABB16	19	50321659	G	А	MED25 (BVFYS; MIM 616449)	Nonsynonymous	NM_030973.3: exon1: c.61G>A: p. Val21Met	0	0

702

703

45	SA11	19	58265432	С	-	ZNF766	Frameshift del	NM_173632.4:c.934delC: p.Arg312Glufs*80	3.266E-5	1.55E-5
46	IABB16	20	2847201	С		<b>VPS16</b> (Dystonia (AD) MIM 619291)	Nonsynonymous	NM_080413.3: exon20: c.2069C>A: p. Ala690Glu	1.99E-05	6.53E-05
47	IABB16	20	16360737	A	G	KIF16B (PMID 29736960)	Nonsynonymous	NM_001199865.2: exon19: c. T1910T>C: p. Val637Ala	0	0
48	IABB5	20	44578999	С		ZNF335 Hu et al, 2019; MCPH10; MIM 615095; Geisinger Tier 4)	Nonsynonymous	NM_022095.3: exon22: c.3346G>A: p. Gly1116Arg	1.26E-5	0
49	IABB11	22	40803252	G		SGSM3 (SFARI score 2; Geisinger Tier 4)	Nonsynonymous	NM_001350039.2:c.1288G>C:p.Glu430Gln	1.99E-5	1.63E-4

<sup>#</sup> SpliceAI predicts the generation of a splice donor site.

Table 3: *De novo* variants. Genes previously reported as pathogenic for ASD/ID or other disorder are indicated, with annotation using (in order of priority): OMIM: <a href="https://omim.org/">https://omim.org/</a>; SFARI ASD genes <a href="https://gene.sfari.org/">https://gene.sfari.org/</a>; DDD gene2phenotype genes: <a href="https://gene.sfari.org/">https://gene.sfari.org/</a>; DDD gene2phenotype genes: <a href="https://gene2phenotype/">https://gene2phenotype/</a>; Geisinger developmental brain disorder gene database: <a href="https://dbd.geisingeradmi.org/">https://dbd.geisingeradmi.org/</a>; NPdenovo: <a href="https://www.wzgenomics.cn/NPdenovo/">http://www.wzgenomics.cn/NPdenovo/</a>; Gene4denovo: <a href="https://www.genemed.tech/gene4denovo/search">https://gene4denovo/search</a>. Genes previously unreported for ASD or ID are in bold type. Control population frequencies shown are from gnomAD (all, and for South Asian sub-population). Allele frequencies are from gnomAD v2.1.1 (www. <a href="https://gnomad.broadinstitute.org/">https://gnomad.broadinstitute.org/</a>; accessed June 2022). All variants were validated by IGV (Integrated Genomics Viewer; Broad Institute) and by Sanger sequencing. Validations are shown in Supplementary Materials.

Variant	Family		Coordinates (hg19)	Ref.	Alt.	Gene (previously reported)	Variant Type		gnomAD All Freq.	gnomAD S. Asian Freq.
1	RQPA20	1	28919246	G	А	RAB42	nonsynonymous	NM_001193532.3: exon1: c. 223G>A: p. Glu75Lys	0	0
2	RQPA20	1	112031311	A	-	TMIGD3	frameshift del	NM_001302680.2: exon2: c.286delT: p. Trp96Glyfs*36	0	0
3	RQPA20	1	150483966	G	Т	ECM1 (DDDG2P: lipoid proteinosis, AR)	Stopgain	NM_001202858.2: exon7: c.823G>T: p. Glu275*	7.96E-06	6.53E-05
4	RQPA20	1	160722912	С	А	SLAMF7	Stopgain	NM_001282589.2: exon5:c.560C>A: p. Ser187*	0	0
5	IAU29	2	1946866	С	-	MYT1L (MRD39: MIM 616521; SFARI score 1; MYT1L)	frameshift del	NM_001303052.2: exon9: c.394delG: p. Glu132Argfs*42	o	0
6	SMPA53	2	166166958	С	Т	SCN2A (DEE11: MIM 6137219; SFARI score 1; Geisinger Tier 1)	Stopgain	NM_001040143.2: exon6:c.823C>T: p. Arg275*	3.98E-06	4.62E-05
7	SMPA38	2	166201156	С	A	SCN2A (DEE11: MIM 6137219; SFARI score 1; Geisinger Tier 1)	Nonsynonymous	S NM_001040143.2:exon15:c.2654C>A:p.Thr885Asn	0	0

8	IAU66	2	232320177	С	-	NCL	frameshift del	NM_005381: exon13: c.1991delG: p. Gly664Glufs*70	0	0
9	SA1	3	38645393	A	Т	SCN5A (BRGDA1: MIM 601144)	Nonsynonymous	NM_198056.3:exon12:c.1700T>A: p.Leu567Gln	8.031E-6	0
10	SMPA75	5	137680632	-	Т	FAM53C	frameshift ins	NM_001135647.2: exon4: c.256dupT: p. Ser86Phefs*14	0	0
11	SMPA75	6	47646871	G	Α	ADGRF2	Splicing	NM_153839.7: exon5: c.267+1G>A	4.01E-06	3.27E-05
12	Autism10	6	87969507- 87969508	AG	-	ZNF292 (MRD64: MIM 619188; SFARI score 1; Geisinger Tier 1)	frameshift del	NM_015021.3: exon8: c.6159_6160del: p. Glu2054Lysfs*14	0	0
13	IAU65	6	87969506- 87969507	AG	-	ZNF292 (MRD64: MIM 619188; SFARI score 1; Geisinger Tier 1)	frameshift del	NM_015021.3: exon8: c.6159_6160del: p. Glu2054Lysfs*14	0	0
14	RQPA20	11	46389550	А	С	DGKZ	Splicing	NM_201533: exon4: c.379-2A>C	0	0
15	Autism9	12	52188238	G	А	SCN8A (DEE13: MIM 614558; SFARI score 1)	Nonsynonymous	NM_014191.4:c.4608G>A: p.Met1536lle	0	0
16	SMPA73	12	89998008	G	С	ATP2B1 (MRD66: MIM 619910; SFARI score 3S)	Stopgain	NM_001001323.2: exon15:c.2558C>G: p. Ser853*	0	0
17	RQPA20	16	89006655	G	Α	LOC100129697/CBFA2T3	Nonsynonymous	NM_001290330.2: exon1: c.53G>A: p. Arg18Lys	0	0
18	SMPA75	19	7734220- 7734221	СТ	-	RETN	frameshift del	NM_001193374.1: exon2: c.8_9del: p. Cys5Serfs*13	4.37E-05	3.27E-04
19	RQPA20	22	20049060	С	G	TANGO2 (Geisinger AR)	Stop gain	NM_152906.7:exon7:c.459C>G: p.Tyr153*	0	0
20	RQPA20	22	22051034	А	G	PPIL2	Splicing	NM_148175: exon21: c.1570-2A>G	0	0

**Table 4: X-linked variants.** Genes previously reported as pathogenic for ASD/ID or other disorder are indicated, with annotation 713 714 using (in order of priority): OMIM: https://omim.org/; SFARI ASD genes https://gene.sfari.org/; DDD gene2phenotype genes: https://www.ebi.ac.uk/gene2phenotype/; Geisinger developmental brain disorder gene database: https://dbd.geisingeradmi.org/; 715 NPdenovo: http://www.wzgenomics.cn/NPdenovo/; Gene4denovo: http://www.genemed.tech/gene4denovo/search. Genes 716 previously unreported for ASD or ID are in bold type. Control population frequencies shown are from gnomAD (all, and for South 717 Asian sub-population). Allele frequencies are from gnomAD v2.1.1 (www. https://gnomad.broadinstitute.org/; accessed June 2022). 718 719 All variants were validated by IGV (Integrated Genomics Viewer; Broad Institute) and by Sanger sequencing. Validations are shown in Supplementary Materials. 720

Variant	Family	Mode of Inheritance	Coordinates (hg19)	Ref	Alt	Gene (previous reports)	Variant Type	cDNA/Amino Acid Change	gnomAD All Freq.	gnomAD S. Asian Freq.
1	SMPA3	Recessive	30236780	С	-	MAGEB2	frameshift del	NM_002364.4:c.83delC:p.Pro28Leufs*84	0	0
2	IAU66	Recessive	48672948	А	G	HDAC6	Nonsynonymous	NM_006044.4:c.908A>G: p.Tyr303Cys	0	0
3	IAU69	Recessive	55779942	Т	С	RRAGB	Nonsynonymous	NM_006064.4: exon7: c.730T>C: p. Phe244Leu	5.49E-06	1.23E-05
4	IAU45	Recessive	64947718	С	Α	MSN	Nonsynonymous	NM_002444.3: exon3: c.139C>A: p. Leu47Met	0	0
5	SMPA15	Recessive	105193588	С	Т	NRK	Stopgain	NM_198465.4: exon27: c.4375C>T: p. Gln1459*	0	0
6	IAU47	Recessive	107170098	A	G	MID2 (MRX101; MIM 300928)	nonsynonymous	NM_012216.4:c.2003A>G:p.Tyr668Cys	0	0
7	IAU24	Recessive	129290446	С	Т	AIFM1 (Cowchock	nonsynonymous	NM_001130847.4: exon2: c. 238G>A: p. Ala80Thr	0	0

						syndr.; MIM 310490)				
8	IAU51	Recessive	140994661	-	А	MAGEC1	frameshift ins	NM_005462.3:c.1471_1472insA; p.Leu491Tyrfs*10	4.37E-05	0
9	IABB8	Recessive	152106616	А	G	ZNF185	Splicing	NM_001178110: exon13: c.942-2A>G	0	0
10	SA1	De Novo	15677205	Т	А	CLTRN (TMEM27)	nonsynonymous &	NM_020665.3:exon3:c.137A>T:p.Glu46V al	0	0
11	SMPA71	De Novo	62926209	G	A	ARHGEF9 (DEE8; MIM 300607; SFARI score 1S; Geisinger Tier1)	nonsynonymous	NM_015185.3: exon3:c.310C>T: :p.Arg104Trp	0	0
12	SMPA84	De Novo	100507601	A	С	DRP2 (CMTX1 MIM 302800; PMID 26227883)	nonsynonymous	NM_001171184.2: exon15: c. 1639A>C: p. Ser547Arg	0	0
13	IAU54	De Novo	153296081	-	Т	MECP2 (RTT; MIM 312750; SFARI score 1; Geisinger Tier1)	frameshift ins	NM_001110792.2:exon3:c.1234dup:p.Th r412Asnfs*5	0	0
14	SMPA78	De Novo	153296516	G	А	MECP2 (RTT; MIM 312750; SFARI score 1' Geisinger Tier1)	Stopgain	NM_001110792.2:exon3:c.799C>T:p. Arg267*	0	0

<sup>&</sup>amp;MutationTaster predicts splice donor created

721

**Table 5: CNV summary:** validated biallelic loss CNVs called by CNVpartition or ChAS. Biallelic losses called from microarray data by PennCNV and from WES data by CLAMMS (80)) did not validate using IGV, and hence are not included. Comparison with control population CNVs used the Database of Genomic Variants (DGV) Gold, accessed through the Decipher genomic browser (<a href="www.deciphergenomics.org">www.deciphergenomics.org</a>), also through gnomAD. Coordinates given using hg19.

Family	Mode of Inheritance	(hg19)	Cytoband	Size (Kb)	CN	CNV confidence	Genes	FREQ IN DGV GOLD STANDARD, gnomAD, or rare?	IGV	PCR
SMPA4	Recessive	14:24,454,924-24,464,325	14q11.2	9.402	0	345.9659	DHRS4 exon 8; DHRS4L2 exons 1-4	Partial overlap with gssvL33876 FREQ 0.0029	Υ	Y
SMPA4	Recessive	20: 43836785-43836964	20q13.12	0.18	0	228.5597	SEMG1 exon 2, 180bp, 60 amino acids	Partial overlap with gssvL72784 FREQ 0.0038	Y	Y
SMPA8	Recessive	2:196,799,394-196,801,362	2q32.3	1.969	0	139.6294	DNAH7 exon 20-21	NONE	Υ	Υ
SMPA3	Recessive	5:140,224,038-140,242,319	5q31.3	18.282	0	1417.866	PCDHA9, PCDHA10 (SFARI score 2)	Also Hom in mother	Y	Υ
IAH2	Recessive	5:140,224,038-140,242,319	5q31.3	18.282	0	1417.866	PCDHA9, PCDHA10 (SFARI score 2)	Also Hom in father	Υ	Υ
IAU79	Recessive	20:1,559,259-1,559,330	20p13	0.072	0	171.6751	SIRPB1 exon 2	Partial OVERLAP WITH COMMON CNV (0.0894)	Υ	Υ
IABB2	Recessive	17:3513856- 3514054	17p13.2	0.198	0	318.3258	SHPK exon 7	Partial OVERLAP WITH 80Kb gssvL47583 (0.00274)	Υ	Υ
IABB14	Recessive	15:85186877-85186894	15q25.2	0.018	0	55.68398	WDR73 exon 8 <sup>\$</sup>	rs760394400; gnomAD MAF 0.1672	Υ	Υ
IABB14	Recessive	19:41356319-41386033	19q13.2	29.714	0	579.0146	CYP2A7 6 exons	gssvL58578 0.002 Plus gssvL58575 0.0017	Υ	Υ

IABB14	Recessive	19: 51330951-51331063	19q13.33	0.112	0	579.0146	KLK15 exon 2	Overlap with gssvL59230 0.02	Y	Y
SMPA42	X-linked	X:47912041-47970683	Xp11.23	58.643	0	1665.299	ZNF630; SSX6	Deletions in ZNF630 do not segregate with ID; PMID 20186789	Υ	
SMPA9	X-linked	X:47917867-47970683	Xp11.23	52.817	0	1558.271	ZNF630; SSX6	Ditto	Y	

<sup>727 \$</sup> see Riazuddin et al, 2017; PMID\_30171209)

**Figure Legends** 

728

729

730

731

732

733

734

735

736

737

738

739

740

741

742

743

744

745


746

747

748

Figure 1: Variant prioritization methods where variants that pass GATK best practices would be filtered for MAF less than or equal to 10<sup>-4</sup> and then categorized into recessive or homozygous variants. Variants are then prioritized based on assessment of potential damage to the protein, and then filtered based on scoring algorithms to predict pathogenicity. Figure 2: Violin plots comparing consanguinity coefficient Froh, for A: different categories of variant identified: All biallelic variants (N=27 observations), variants in known AR ID and/or ASD genes (N=10 observations), variants in novel candidate genes (N=17 observations), all X-linked (XL) variants plus de novo autosomal dominant (AD) variants (N=18 observations), variants in known XL and AD genes (N=11 observations), and variants in novel candidate XL and AD genes (N=7 observations). Unpaired t test (2-tailed) for comparison of means showed comparison for i) all biallelic versus all de novo autosomal plus X-linked to be extremely significant (p<0.0001, t=5.8309, d.f.=51), ii) known AR versus AD ID and/or ASD genes to be strongly significant (p=0.0045, t=3.1642, d.f.=22), iii) novel candidate AR versus AD genes to be strongly significant (p<0.0001, t=5.4795, d.f.=26). No significant difference in mean  $F_{roh}$  was seen for comparisons between known and novel candidate AR genes, or between known and novel AD plus XL genes; B: different cohorts, categorized by last name of principal investigator for each collection (Agha, N=3, Ansar, N=52, Heidari, N=2, Al Ayadhi, N=13, Bozorgmehr, N=10, Sasanfar, N=24 observations). While F<sub>roh</sub> distribution was similar for most cohorts, the Iranian cohort from Sasanfar had a significantly lower mean than most other cohorts; C: grouped by country of

origin (Pakistan, N=55, Iran, N= 36, Saudi Arabia=13 observations). Comparison of mean F<sub>roh</sub> was non-significant for Pakistan versus Iran and versus Saudi Arabia, but significant for Iran versus Saudi Arabia, but non-significant after correction for multiple testing (p=0.0206, t=2.396, d.f.=36). Plots were prepared using R software using ggplot2, and show mean, standard deviation, and outliers marked by "X".



755

